<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="dict8/PMC7283747/results/search/disease/results.xml">
  <result pre="Special Issue: Special Issue How did we get here? A" exact="short" post="history of COVID‐19 and other coronavirus‐related epidemics Lango LangoMiriam"/>
  <result pre="LangoMiriam N.MDhttps://orcid.org/0000-0003-0736-74731mnlango@mdanderson.org[1], Department of Head and Neck SurgeryM. D. Anderson" exact="Cancer" post="Center HoustonTexasUSA *Correspondence Miriam N. Lango, MD, M. D."/>
  <result pre="Center HoustonTexasUSA *Correspondence Miriam N. Lango, MD, M. D. Anderson" exact="Cancer" post="Center, 1515 Holcombe Blvd, Houston, TX 77030, Email: MNLango@mdanderson.org"/>
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="closely resembles SARS CoV‐1, which was responsible for the severe" exact="acute" post="respiratory syndrome (SARS) outbreak in 2002. SARS CoV‐1 and"/>
  <result pre="resembles SARS CoV‐1, which was responsible for the severe acute" exact="respiratory" post="syndrome (SARS) outbreak in 2002. SARS CoV‐1 and 2"/>
  <result pre="SARS CoV‐1, which was responsible for the severe acute respiratory" exact="syndrome" post="(SARS) outbreak in 2002. SARS CoV‐1 and 2 share"/>
  <result pre="sequences and use the same host cell receptor to initiate" exact="viral infection." post="However, SARS predominantly affected individuals in close contact with"/>
  <result pre="the current status of vaccine trials. coronavirus COVID‐19 otolaryngology head" exact="and neck" post="surgery review fig-count: table-count: page-count: word-count: LangoMN. How did"/>
  <result pre="table-count: page-count: word-count: LangoMN. How did we get here? A" exact="short" post="history of COVID‐19 and other coronavirus‐related epidemics. Head &amp;amp;"/>
  <result pre="noticed a series of patients showing signs of a severe" exact="acute" post="respiratory syndrome or SARS‐like illness which was subsequently reported"/>
  <result pre="a series of patients showing signs of a severe acute" exact="respiratory" post="syndrome or SARS‐like illness which was subsequently reported to"/>
  <result pre="series of patients showing signs of a severe acute respiratory" exact="syndrome" post="or SARS‐like illness which was subsequently reported to the"/>
  <result pre="Emergency of International Concern (PHEIC). The first case of the" exact="disease" post="due to local person to person spread in the"/>
  <result pre="for the &quot;common cold,&quot; accounting for up to 30% of" exact="upper" post="respiratory tract infections in adults. Coronaviruses, like other RNA"/>
  <result pre="the &quot;common cold,&quot; accounting for up to 30% of upper" exact="respiratory" post="tract infections in adults. Coronaviruses, like other RNA viruses,"/>
  <result pre="cold,&quot; accounting for up to 30% of upper respiratory tract" exact="infections" post="in adults. Coronaviruses, like other RNA viruses, mutate frequently"/>
  <result pre="most significant, growing threat to global health of all emerging" exact="infectious" post="diseases.1 Geographic hotspots, or maps reflecting zoonotic infectious disease"/>
  <result pre="growing threat to global health of all emerging infectious diseases.1" exact="Geographic" post="hotspots, or maps reflecting zoonotic infectious disease risk have"/>
  <result pre="all emerging infectious diseases.1 Geographic hotspots, or maps reflecting zoonotic" exact="infectious disease" post="risk have been identified in South American, Africa and"/>
  <result pre="emerging infectious diseases.1 Geographic hotspots, or maps reflecting zoonotic infectious" exact="disease" post="risk have been identified in South American, Africa and"/>
  <result pre="Heat maps of predicted relative risk distribution of zoonotic emerging" exact="disease" post="threats. The CoV‐2 coronavirus arose in one of these"/>
  <result pre="another outbreak, referred to as MERS for the Middle Eastern" exact="Respiratory" post="Syndrome, and also caused by a coronavirus, resulted in"/>
  <result pre="and also caused by a coronavirus, resulted in over 1000" exact="infections" post="and 400 deaths through 2015. Since SARS and MERS"/>
  <result pre="settings were the most frequent sites of person to person" exact="disease" post="transmission.5, 6 Health care workers and those in close"/>
  <result pre="these outbreaks. In particular, otolaryngologists were at greater risk of" exact="infection" post="due to shedding of virus from nasal and pharyngeal"/>
  <result pre="of virus from nasal and pharyngeal mucosa.7 The implementation of" exact="infection" post="control methods, aggressive contact tracing and isolation limited the"/>
  <result pre="implementation of infection control methods, aggressive contact tracing and isolation" exact="limited" post="the spread of disease in 2003 and 2012. Antiviral"/>
  <result pre="methods, aggressive contact tracing and isolation limited the spread of" exact="disease" post="in 2003 and 2012. Antiviral treatments and vaccines were"/>
  <result pre="SARS‐CoV‐1.8 SARS‐CoV‐2 is more closely related to two bat‐derived severe" exact="acute" post="respiratory syndrome (SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in"/>
  <result pre="SARS‐CoV‐2 is more closely related to two bat‐derived severe acute" exact="respiratory" post="syndrome (SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in 2018"/>
  <result pre="is more closely related to two bat‐derived severe acute respiratory" exact="syndrome" post="(SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in 2018 in"/>
  <result pre="is believed to have occurred from a bat‐CoV to an" exact="intermediate" post="host after which the virus jumped to human hosts"/>
  <result pre="high rates of asymptomatic carriers which promote the spread of" exact="infection" post="to susceptible populations,13 rather than greater stability of virus"/>
  <result pre="than CoV‐1.15 3SARS‐COV2: CONSERVED SEQUENCES AND GENETIC DRIFT While the" exact="viral" post="genome continues to evolve since entering the human population,"/>
  <result pre="on electron micrographs, mediates binding to host cell receptors, determines" exact="viral" post="host range and tissue tropism, and induces host immune"/>
  <result pre="receptor mediates the effects of angiotensin, which affects vasoconstriction and" exact="hypertension" post="in the lungs, heart, kidneys and intestines. An identical"/>
  <result pre="coronaviruses plays an important role in the first step of" exact="viral infection" post="by binding to the host ACE‐2 receptor, and initiating"/>
  <result pre="plays an important role in the first step of viral" exact="infection" post="by binding to the host ACE‐2 receptor, and initiating"/>
  <result pre="are highly conserved, since they are necessary to propagate the" exact="infection" post="in person to person spread. The amino acid sequence"/>
  <result pre="in coronaviruses is uncertain. In general, immune responses to coronavirus" exact="infections" post="confer prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that"/>
  <result pre="confer prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that prevent" exact="viral infection" post="by preventing binding of the S protein to the"/>
  <result pre="prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that prevent viral" exact="infection" post="by preventing binding of the S protein to the"/>
  <result pre="detected in patients with SARS almost 20 years after recovering from" exact="disease" post="suggesting that patients retain protection over long periods after"/>
  <result pre="While the genetic sequences critical to transmission are preserved, noncritical" exact="viral" post="sequences have undergone genetic drift. Compared to CoV‐2 sequences"/>
  <result pre="distinguish European from Asian SARS CoV‐2 coronavirus strains.18 Differences between" exact="viral" post="strains has permitted evaluations of the effectiveness of public"/>
  <result pre="States.19 4 SEROLOGICAL TESTING AND VACCINE DEVELOPMENT The identification of" exact="viral" post="epitopes that stimulate the production of antibodies that serve"/>
  <result pre="that serve as markers of an immune response to CoV‐2" exact="infection" post="are necessary for the development of serologic testing and"/>
  <result pre="design of a SARS‐CoV‐2 vaccine. However, not all antibodies prevent" exact="viral infection," post="despite targeting virus specific epitopes. For example, antibodies raised"/>
  <result pre="example, antibodies raised against SARS CoV‐1 cross‐react with the CoV‐2" exact="viral" post="epitopes, but do not prevent CoV‐2 binding to ACE‐1"/>
  <result pre="these antibodies may provide some clinical protection or attenuate the" exact="disease" post="without actually preventing infection.21, 22 Neutralizing antibodies that prevent"/>
  <result pre="disease without actually preventing infection.21, 22 Neutralizing antibodies that prevent" exact="viral" post="attachment to host cell receptors protect against viral infection."/>
  <result pre="that prevent viral attachment to host cell receptors protect against" exact="viral infection." post="However, subtle amino acid alterations may provide a &quot;back"/>
  <result pre="subtle amino acid alterations may provide a &quot;back door&quot; for" exact="viral" post="escape mutants16. A cocktail of viral epitopes to stimulate"/>
  <result pre="a &quot;back door&quot; for viral escape mutants16. A cocktail of" exact="viral" post="epitopes to stimulate a robust neutralizing immunologic response has"/>
  <result pre="development for SARS. Anecdotal reports of individuals developing more severe" exact="disease" post="after exposure in individuals vaccinated against SARS CoV‐1 raised"/>
  <result pre="Animal models demonstrated an analogous effect. Prior immunization with severe" exact="acute" post="respiratory syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe"/>
  <result pre="models demonstrated an analogous effect. Prior immunization with severe acute" exact="respiratory" post="syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe pneumonia"/>
  <result pre="demonstrated an analogous effect. Prior immunization with severe acute respiratory" exact="syndrome" post="(SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe pneumonia in"/>
  <result pre="acute respiratory syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe" exact="pneumonia" post="in mice infected with SARS‐CoV.27 Demonstrations of safety and"/>
  <result pre="REFERENCES 1JonesKE, PatelNG, LevyMA, et al. Global trends in emerging" exact="infectious diseases." post="Nature. 2008;451(7181):990‐993.18288193 2AllenT, MurrayKA, Zambrana‐TorrelioC, et al. Global hotspots"/>
  <result pre="emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523‐534.27344959 7AlexanderAJ, TanAK, EvansGA, AllenJ." exact="Infection" post="control for the otolaryngologist in the era of severe"/>
  <result pre="Infection control for the otolaryngologist in the era of severe" exact="acute" post="respiratory syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et"/>
  <result pre="control for the otolaryngologist in the era of severe acute" exact="respiratory" post="syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et al."/>
  <result pre="syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="10LiJY, YouZ, WangQ, et al. The epidemic of 2019‐novel‐coronavirus (2019‐nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the future."/>
  <result pre="The epidemic of 2019‐novel‐coronavirus (2019‐nCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the future. Microbes Infect. 2020;22(2):80‐85.32087334 11HaoP, ZhongW, SongS,"/>
  <result pre="analysis. Ann Transl Med. 2020;8(4):128.32175421 16RockxB, CortiD, DonaldsonE, et al." exact="Structural" post="basis for potent cross‐neutralizing human monoclonal antibody protection against"/>
  <result pre="human monoclonal antibody protection against lethal human and zoonotic severe" exact="acute" post="respiratory syndrome coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing"/>
  <result pre="monoclonal antibody protection against lethal human and zoonotic severe acute" exact="respiratory" post="syndrome coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing antibody"/>
  <result pre="antibody protection against lethal human and zoonotic severe acute respiratory" exact="syndrome" post="coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing antibody tests"/>
  <result pre="2020. 20ChengMP, PapenburgJ, DesjardinsM, et al. Diagnostic testing for severe" exact="acute" post="respiratory syndrome‐related coronavirus‐2:a narrative review. Ann Intern Med. 202010.7326/M20-1301."/>
  <result pre="20ChengMP, PapenburgJ, DesjardinsM, et al. Diagnostic testing for severe acute" exact="respiratory" post="syndrome‐related coronavirus‐2:a narrative review. Ann Intern Med. 202010.7326/M20-1301. 21HoffmannM,"/>
  <result pre="2020;368:630‐633.32245784 23CoughlinMM, BabcookJ, PrabhakarBS. Human monoclonal antibodies to SARS‐coronavirus inhibit" exact="infection" post="by different mechanisms. Virology. 2009;394(1):39‐46.19748648 24LinJT, ZhangJS, SuN, et"/>
  <result pre="and immunogenicity from a phase I trial of inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM,"/>
  <result pre="immunogenicity from a phase I trial of inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM, HatchettR,"/>
  <result pre="from a phase I trial of inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM, HatchettR, HaltonJ."/>
  <result pre="N Engl J Med. 202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of" exact="virus infection" post="and disease. Viral Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et"/>
  <result pre="Engl J Med. 202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of virus" exact="infection" post="and disease. Viral Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et"/>
  <result pre="202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of virus infection and disease." exact="Viral" post="Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et al. Prior immunization"/>
  <result pre="2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et al. Prior immunization with severe" exact="acute" post="respiratory syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe"/>
  <result pre="27YasuiF, KaiC, KitabatakeM, et al. Prior immunization with severe acute" exact="respiratory" post="syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe pneumonia"/>
  <result pre="KaiC, KitabatakeM, et al. Prior immunization with severe acute respiratory" exact="syndrome" post="(SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe pneumonia in"/>
  <result pre="acute respiratory syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe" exact="pneumonia" post="in mice infected with SARS‐CoV. J Immunol. 2008;181(9):6337‐6348.18941225 28MitsukiYY,"/>
  <result pre="neutralization affects in vitro and in vivo fitness of severe" exact="acute" post="respiratory syndrome coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter"/>
  <result pre="affects in vitro and in vivo fitness of severe acute" exact="respiratory" post="syndrome coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter MeulenJ,"/>
  <result pre="in vitro and in vivo fitness of severe acute respiratory" exact="syndrome" post="coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter MeulenJ, van"/>
  <result pre="Med. 2006;3(7):e23716796401 31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe" exact="acute" post="respiratory syndrome coronavirus: target, mechanism of action, and therapeutic"/>
  <result pre="2006;3(7):e23716796401 31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe acute" exact="respiratory" post="syndrome coronavirus: target, mechanism of action, and therapeutic potential."/>
  <result pre="31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe acute respiratory" exact="syndrome" post="coronavirus: target, mechanism of action, and therapeutic potential. Rev"/>
 </snippets>
</snippetsTree>
